| P2093 | author name string | N J Vogelzang | |
| | B Roth | |
| | E Levine | |
| | W M Stadler | |
| | D Raghavan | |
| | T M Kuzel | |
| | F A Dorr | |
| P2860 | cites work | Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors | Q70395690 |
| | MVAC for bladder cancer: time to move forward again | Q70590723 |
| | Cis-diamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma | Q70646191 |
| | Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer | Q70648915 |
| | Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer | Q70661796 |
| | A phase 2 study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group | Q70668200 |
| | Treatment of invasive bladder cancer by local resection and high dose methotrexate | Q70779075 |
| | Single-drug chemotherapy with 5-FU and adriamycin in metastatic bladder cancer | Q70866073 |
| | Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study | Q71228627 |
| | Phase-II trials in patients with urothelial tract tumors. Memorial Sloan-Kettering Cancer Center | Q71238240 |
| | Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium | Q93606365 |
| | Dose response evaluation of adriamycin in human neoplasia | Q28331491 |
| | Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 |
| | Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma | Q33488035 |
| | Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer | Q33489195 |
| | Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 |
| | A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. | Q33493937 |
| | Biology and management of bladder cancer | Q37911018 |
| | Methotrexate: an active drug in bladder cancer | Q40279428 |
| | Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial | Q40704537 |
| | A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 |
| | Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium | Q40785644 |
| | Methotrexate in the Treatment of Metastatic and Recurrent Primary Transitional Cell Carcinoma | Q42244281 |
| | A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. | Q42267589 |
| | Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 |
| | Cancer statistics, 1995. | Q43686273 |
| | Gallium nitrate in advanced bladdercarcinoma: Southwest oncology group study | Q44231562 |
| | Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. | Q51842811 |
| | Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer? | Q54320248 |
| | The Treatment of Advanced Bladder Cancer with Methotrexate | Q67051628 |
| | Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study | Q67330033 |
| | Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors | Q68032662 |
| | Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate | Q68072448 |
| | A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 |
| | Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | Q69401186 |
| P304 | page(s) | S23-6 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Metastatic bladder cancer: advances in treatment | |
| P478 | volume | 33 Suppl 1 | |